Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Mon, 19.04.2021       CureVac

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic - Rolling submission to accelerate time to marketing authorization of CVnCoV in Switzerland - Review process started with submission of first CVnCoV data package TÜBINGEN, Germany/ BOSTON, USA - April 19, 2021 - The CureVac S [ … ]
Thu, 15.04.2021       CureVac

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited [ … ]
Fri, 09.04.2021       CureVac

CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 TÜBINGEN, Germany/ BOSTON, USA - April 9, 2021 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results and bus [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 06.10.2024, Calendar Week 40, 280th day of the year, 86 days remaining until EoY.